Compensatory reactions during impairment of granulocytic stem in patients with lung cancer receiving antitumor chemotherapy.
We compared changes in the granulocytic hemopoietic stem in patients with stage III-IV lung cancer receiving cytostatic therapy by the original CVC and standard CAM schemes. In patients treated with the CVC regimen, the granulocytic hemopoietic stem possessed more potent compensatory capacities.
Gol'dberg
V E
VE
Institute of Pharmacology, Tomsk Research Center, Siberian Division of the Russian Academy of Medical Sciences.
Zhdanov
V V
VV
Matyash
M G
MG
Simolina
E I
EI
Khrichkova
T Y
TY
Vysotskaya
V V
VV
Popova
N O
NO
Boldyshev
D A
DA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D016190:Carboplatin / Q000494:pharmacology / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use; D006098:Granulocytes / Q000187:drug effects / Q000473:pathology; D006801:Humans; D019891:Leukopoiesis / Q000187:drug effects*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D008727:Methotrexate / Q000494:pharmacology / Q000627:therapeutic use; D014750:Vincristine / Q000494:pharmacology / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D008727:Methotrexate